Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508231 | 0.92 | L3MBTL1 (0.35) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL508747 | 0.90 | MEN1 (0.35) | L3MBTL1KDM4CNPC1RAB9AP2RX3 | |
| SCHEMBL14599714 | 0.90 | L3MBTL1 (0.36) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL509945 | 0.88 | L3MBTL1 (0.35) | L3MBTL1KDM4CNPC1RAB9AP2RX3 | |
| SCHEMBL508458 | 0.84 | NPC1 (0.38) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL509573 | 0.83 | KCNH2 (0.37) | KDM4CNPC1RAB9AP2RX3MEN1 | |
| SCHEMBL509150 | 0.82 | KDM4C (0.35) | L3MBTL1KDM4CNPC1RAB9AP2RX3 | |
| SCHEMBL508425 | 0.82 | MET (0.34) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL508220 | 0.80 | MET (0.35) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL509390 | 0.78 | MET (0.36) | KDM4CNPC1RAB9AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | L3MBTL1 611/4885KDM4C 1498/4885NPC1 3331/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | L3MBTL1 848/4885KDM4C 1561/4885NPC1 3490/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | L3MBTL1 2125/4885KDM4C 2153/4885NPC1 2912/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | L3MBTL1 1876/4885KDM4C 2413/4885NPC1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.